Carrick licenses targeted ovarian cancer drug from BTG
Dublin, Ireland-based biopharma Carrick Therapeutics has licensed exclusive globl rights to develop and commercialise BTG’s targeted ovarian cancer drug BTG945.
The investigational drug, a combination of the targeting folate receptor α (FRα) and inhibiting thymidylate synthase, will now be referred to as CT900.
The small molecule compound – discovered by the Institute of Cancer Research - selectively enters cancer cells that over express folate receptor α (FRα) versus normal tissues and inhibits thymidylate synthase, leading to cell death.
Read more: http://www.pharmatimes.com/news/carrick_licenses_targeted_ovarian_cancer_drug_from_btg_1255359
The investigational drug, a combination of the targeting folate receptor α (FRα) and inhibiting thymidylate synthase, will now be referred to as CT900.
The small molecule compound – discovered by the Institute of Cancer Research - selectively enters cancer cells that over express folate receptor α (FRα) versus normal tissues and inhibits thymidylate synthase, leading to cell death.
Read more: http://www.pharmatimes.com/news/carrick_licenses_targeted_ovarian_cancer_drug_from_btg_1255359